Menu
Menu
Menu
Learn about the specialised instruments used by (Adj) Professor Theo Kofidis in keyhole heart surgeries.
Rethinking Stem Cell Therapy
(Adj) Professor Theo Kofidis addresses the challenges of advanced heart disease treatment and explores the potential of stem cell therapies. Emphasising the limitations of current treatments,
(Adj) Professor Kofidis highlights the promise of using stem cells to restore heart muscle function. He discusses innovative approaches, such as combining stem cells with anti-inflammatory drugs and antioxidants, which have shown promising results in improving heart function in animal studies.
(Adj) Professor Kofidis's team has received a grant to further these experiments, aiming to refine techniques before moving to human trials. This underscores a hopeful outlook for advancing heart disease treatment through pioneering biomedical research.
From Six Cuts To One
(Adj) Professor Theo Kofidis has introduced a groundbreaking single-incision technique for repairing faulty heart valves at the National University Heart Centre, Singapore. Traditionally, surgeries for mitral and tricuspid valve diseases required multiple incisions. However, (Adj) Professor Kofidis has streamlined the procedure to involve just one 6 cm incision between the ribs, eliminating the need for additional ports. This innovative approach uses modified surgical tools, including a flexible steel plate to hold the heart incision open and a specialised aortic cross clamp. Besides improving cosmetic outcomes, the technique aims to reduce surgical complications and recovery time, setting a new standard in minimally invasive cardiac surgery.
(Adj) Professor Theo Kofidis has led a team of clinician-scientists in developing SingValve, a groundbreaking personalised mitral valve bioprosthesis. This innovative valve closely mimics the human mitral valve’s appearance, form, and physical properties. The project, awarded a $4.9 million grant from the National Research Foundation Singapore (NRF), aims to advance product verification and validation through extensive testing and comparative studies. First-in-human trials are expected by 2023. SingValve’s success could significantly boost Singapore’s MedTech industry, creating jobs and enhancing medical tourism.
(Adj) Professor Theo Kofidis led a team that developed SingValve, a personalised mitral valve bioprosthesis. SingValve mimics a human mitral valve’s appearance and properties, based on patient scans. Awarded a USD 3.6 million (SGD 4.9 million) grant from the National Research Foundation Singapore (NRF), the project will advance through product verification and validation. First-in-human trials are expected by 2023. SingValve aims to revolutionise heart valve surgery, boosting Singapore’s MedTech industry and medical tourism.
(Adj) Professor Theo Kofidis, leading a team at the National University Health System (NUHS) in Singapore, spearheaded the development of SingValve, a groundbreaking mitral valve bioprosthesis. This innovative implant, designed to mimic the natural human mitral valve, addresses the limitations of current artificial valves by offering flexibility and customization based on individual patient needs. Under his leadership, SingValve has received significant funding from the NRF Central Gap Fund to advance through rigorous testing and validation stages, aiming for first-in human trials by 2023. (Adj) Professor Kofidis emphasises SingValve’s potential to set new standards in cardiac surgery, positioning Singapore as a hub for cutting-edge medical technology and innovation.
New Invention A Plus For Heart Surgery
(Adj) Professor Theo Kofidis introduces the Endopsis system, a groundbreaking innovation in minimally invasive heart surgery. This flexible, miniature video camera, integrated into a surgical instrument, replaces bulky camera systems, reducing trauma and hastening recovery for patients. The Endopsis system, developed at the National University Heart Centre Singapore, allows for fewer incisions, a clearer operative field, and has shown promising results in clinical trials, significantly advancing heart surgery techniques and patient outcomes.
(Adj) Professor Theo Kofidis, leading the Cardiac, Thoracic, and Vascular Surgery Simulation Centre at NUHCS, emphasises its role in training surgeons on advanced cardiothoracic and vascular techniques. The centre, equipped with digital and mechanical simulators, aims to shorten the learning curve for complex surgeries like minimally invasive mitral valve procedures. It accommodates over 1,000 clinicians annually from various countries, enhancing skills crucial for modern surgical practices while reducing training time on real patients.
(Adj) Professor Theo Kofidis introduces “The Singapore Correction,” a set of 12 innovative techniques aimed at standardising and simplifying mitral valve repair surgery. These intuitive methods reduce the risk of repair failures and make the procedure more accessible to less experienced surgeons, potentially lowering the threshold for successful mitral valve repairs. Inspired by Greek mythology and Roman architecture, these techniques enhance consistency in patient outcomes and have already shown promising results in clinical applications, marking a significant advancement in cardiac surgery.
In an initiative led by (Adj) Professor Theo Kofidis, the National University Heart Centre, Singapore (NUHCS), is advancing cardiac surgery through the CTVS Simulation Centre, which provides realistic training with over 20 types of simulators. This initiative enhances surgeon skills in a safe environment, bridging the gap between theoretical learning and real-life practice. Additionally, (Adj) Professor Kofidis has developed “The Singapore Correction,” a series of 12 novel mitral valve surgery techniques designed to standardise procedures and improve patient outcomes.
In this podcast, (Adj) Professor Theo Kofidis discusses the complexities of myocardial bridges and the advancements in minimally invasive heart surgery. He emphasises the importance of patient education and understanding the condition, sharing insights from his experiences in Europe and the United States. The conversation covers the intricacies of unroofing procedures, the need for customised patient-centric approaches, and the challenges in diagnosing myocardial bridges.
“All Isolated MVR Surgery Should Be Done Minimally Invasively”
(Adj) Professor Theo Kofidis advocates for the widespread adoption of minimally invasive mitral valve surgery (MICS) based on compelling evidence of its safety and efficacy. Drawing on studies from institutions like the Leipzig Heart Center and New York University Medical Center, he highlights that MICS offers comparable outcomes to traditional sternotomy but with advantages such as shorter hospital stays, reduced blood loss, and improved cosmetic results. Despite initial scepticism, studies demonstrate that MICS is feasible even in complex cases like obese patients or those with left ventricular dysfunction.
Rethinking Stem Cell Therapy
(Adj) Professor Theo Kofidis addresses the challenges of advanced heart disease treatment and explores the potential of stem cell therapies. Emphasising the limitations of current treatments, (Adj) Professor Kofidis highlights the promise of using stem cells to restore heart muscle function. He discusses innovative approaches, such as combining stem cells with anti-inflammatory drugs and antioxidants, which have shown promising results in improving heart function in animal studies. (Adj) Professor Kofidis's team has received a grant to further these experiments, aiming to refine techniques before moving to human trials. This underscores a hopeful outlook for advancing heart disease treatment through pioneering biomedical research.
From Six Cuts To One
(Adj) Professor Theo Kofidis has introduced a groundbreaking single-incision technique for repairing faulty heart valves at the National University Heart Centre, Singapore. Traditionally, surgeries for mitral and tricuspid valve diseases required multiple incisions. However, (Adj) Professor Kofidis has streamlined the procedure to involve just one 6 cm incision between the ribs, eliminating the need for additional ports. This innovative approach uses modified surgical tools, including a flexible steel plate to hold the heart incision open and a specialised aortic cross clamp. Besides improving cosmetic outcomes, the technique aims to reduce surgical complications and recovery time, setting a new standard in minimally invasive cardiac surgery.
(Adj) Professor Theo Kofidis has led a team of clinician-scientists in developing SingValve, a groundbreaking personalised mitral valve bioprosthesis. This innovative valve closely mimics the human mitral valve’s appearance, form, and physical properties. The project, awarded a $4.9 million grant from the National Research Foundation Singapore (NRF), aims to advance product verification and validation through extensive testing and comparative studies. First-in-human trials are expected by 2023. SingValve’s success could significantly boost Singapore’s MedTech industry, creating jobs and enhancing medical tourism.
(Adj) Professor Theo Kofidis led a team that developed SingValve, a personalised mitral valve bioprosthesis. SingValve mimics a human mitral valve’s appearance and properties, based on patient scans. Awarded a USD 3.6 million (SGD 4.9 million) grant from the National Research Foundation Singapore (NRF), the project will advance through product verification and validation. First-in-human trials are expected by 2023. SingValve aims to revolutionise heart valve surgery, boosting Singapore’s MedTech industry and medical tourism.
(Adj) Professor Theo Kofidis, leading a team at the National University Health System (NUHS) in Singapore, spearheaded the development of SingValve, a groundbreaking mitral valve bioprosthesis. This innovative implant, designed to mimic the natural human mitral valve, addresses the limitations of current artificial valves by offering flexibility and customization based on individual patient needs. Under his leadership, SingValve has received significant funding from the NRF Central Gap Fund to advance through rigorous testing and validation stages, aiming for first-in human trials by 2023. (Adj) Professor Kofidis emphasises SingValve’s potential to set new standards in cardiac surgery, positioning Singapore as a hub for cutting-edge medical technology and innovation.
New Invention A Plus For Heart Surgery
(Adj) Professor Theo Kofidis introduces the Endopsis system, a groundbreaking innovation in minimally invasive heart surgery. This flexible, miniature video camera, integrated into a surgical instrument, replaces bulky camera systems, reducing trauma and hastening recovery for patients. The Endopsis system, developed at the National University Heart Centre Singapore, allows for fewer incisions, a clearer operative field, and has shown promising results in clinical trials, significantly advancing heart surgery techniques and patient outcomes.
(Adj) Professor Theo Kofidis, leading the Cardiac, Thoracic, and Vascular Surgery Simulation Centre at NUHCS, emphasises its role in training surgeons on advanced cardiothoracic and vascular techniques. The centre, equipped with digital and mechanical simulators, aims to shorten the learning curve for complex surgeries like minimally invasive mitral valve procedures. It accommodates over 1,000 clinicians annually from various countries, enhancing skills crucial for modern surgical practices while reducing training time on real patients.
(Adj) Professor Theo Kofidis introduces “The Singapore Correction,” a set of 12 innovative techniques aimed at standardising and simplifying mitral valve repair surgery. These intuitive methods reduce the risk of repair failures and make the procedure more accessible to less experienced surgeons, potentially lowering the threshold for successful mitral valve repairs. Inspired by Greek mythology and Roman architecture, these techniques enhance consistency in patient outcomes and have already shown promising results in clinical applications, marking a significant advancement in cardiac surgery.
In an initiative led by (Adj) Professor Theo Kofidis, the National University Heart Centre, Singapore (NUHCS), is advancing cardiac surgery through the CTVS Simulation Centre, which provides realistic training with over 20 types of simulators. This initiative enhances surgeon skills in a safe environment, bridging the gap between theoretical learning and real-life practice. Additionally, (Adj) Professor Kofidis has developed “The Singapore Correction,” a series of 12 novel mitral valve surgery techniques designed to standardise procedures and improve patient outcomes.
In this podcast, (Adj) Professor Theo Kofidis discusses the complexities of myocardial bridges and the advancements in minimally invasive heart surgery. He emphasises the importance of patient education and understanding the condition, sharing insights from his experiences in Europe and the United States. The conversation covers the intricacies of unroofing procedures, the need for customised patient-centric approaches, and the challenges in diagnosing myocardial bridges.
“All Isolated MVR Surgery Should Be Done Minimally Invasively”
(Adj) Professor Theo Kofidis advocates for the widespread adoption of minimally invasive mitral valve surgery (MICS) based on compelling evidence of its safety and efficacy. Drawing on studies from institutions like the Leipzig Heart Center and New York University Medical Center, he highlights that MICS offers comparable outcomes to traditional sternotomy but with advantages such as shorter hospital stays, reduced blood loss, and improved cosmetic results. Despite initial scepticism, studies demonstrate that MICS is feasible even in complex cases like obese patients or those with left ventricular dysfunction.
Monday to Friday
08:30 – 17:30
Saturday
08:30 – 12:30
3 Mount Elizabeth,
MEMC #16-02
Singapore 228510
© 2024 Theo Kofidis | WWW.CARDIACSURGERY.COM.SG